Bioverativ

Metagenomi Appoints Luis Borges, Ph.D., as Chief Scientific Officer and Pamela Wapnick, MBA, as Chief Financial Officer

Retrieved on: 
Thursday, November 9, 2023

“I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi.

Key Points: 
  • “I am excited to welcome Luis and Pamela to expand the scientific and financial strength of our leadership team,” said Brian C. Thomas, Ph.D., CEO and founder of Metagenomi.
  • Dr. Borges was most recently Chief Scientific Officer at Century Therapeutics, where he successfully built a multifunctional discovery and translational research organization.
  • Prior to Century, he served as Chief Scientific Officer at Cell Medica, Senior Vice President of Research at Five Prime Therapeutics, and Scientific Director in Amgen’s Therapeutic Innovation Unit.
  • As Chief Financial Officer at True North Therapeutics, Pamela completed preparations for an initial public offering before the company’s acquisition by Bioverativ.

Scholar Rock Announces the Addition of Richard Brudnick to Its Board of Directors

Retrieved on: 
Monday, April 10, 2023

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Richard Brudnick, has been appointed to Scholar Rock’s Board of Directors as an independent director.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Richard Brudnick, has been appointed to Scholar Rock’s Board of Directors as an independent director.
  • Mr. Brudnick is an accomplished biotechnology executive with over three decades of industry experience specializing in the corporate development of companies spanning across multiple specialties, stages and therapeutic areas.
  • View the full release here: https://www.businesswire.com/news/home/20230410005287/en/
    “We are pleased to welcome Richard to Scholar Rock’s Board of Directors.
  • Richard brings extensive corporate development experience and leadership acumen, having held several executive positions and currently serving as Chief Business Officer of Prime Medicine, which will be instrumental as Scholar Rock advances towards becoming a fully integrated biopharmaceutical company,” said David Hallal, Chairman of the Board of Scholar Rock.

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, February 23, 2023

“Lynn possesses more than 25 years of experience in the pharmaceutical industry, including leadership positions at both large and emerging pharmaceutical companies.

Key Points: 
  • “Lynn possesses more than 25 years of experience in the pharmaceutical industry, including leadership positions at both large and emerging pharmaceutical companies.
  • As our newly appointed Vice President, Clinical Operations, she will be responsible for driving the clinical development of our EVM201 and EVM301 product platforms,” said Joseph Tucker, Ph.D., Director and CEO of Enveric Bioscience.
  • Prior to BlueRock, Ms. Gallant served as Executive Director, Clinical Operations at Bioverativ, a Sanofi Genzyme company.
  • The grant was approved by the board of directors of the Company and made as an inducement material to Ms. Gallant entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Monday, November 7, 2022

BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately.

Key Points: 
  • BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately.
  • Mr. Ian Mortimer, Xenons President and Chief Executive Officer, stated, We are very pleased to welcome Andrea to Xenons senior leadership team in the newly created role of Chief Legal Officer.
  • From 2019 to 2020, Ms. DiFabio served as Chief Legal Officer and Corporate Secretary at Codiak Biosciences, Inc.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Diality Names Pamela Wapnick as Chief Financial Officer

Retrieved on: 
Thursday, September 15, 2022

Diality Inc., a medical technology company developing a smart, mobile hemodialysis platform, today announced the hiring of Pamela Wapnick as chief financial officer.

Key Points: 
  • Diality Inc., a medical technology company developing a smart, mobile hemodialysis platform, today announced the hiring of Pamela Wapnick as chief financial officer.
  • At Graybug Vision, Wapnick raised $55 million in Series C financing, and completed multiple audits.
  • Diality is developing a smart hemodialysis platform designed to be as powerful and flexible as in-center treatment, in a small, easy-to-use device.
  • Pam is a proven leader with decades of financial and fundraising expertise, both in the private sector and in the capital markets, said Dr. Osman Khawar, chief executive officer at Diality.

Prime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio

Retrieved on: 
Thursday, July 28, 2022

Together, they bring strong business acumen, extensive clinical and regulatory experience and leadership of successful teams that position us well to achieve our mission, said Keith Gottesdiener, M.D., Chief Executive Officer of Prime Medicine.

Key Points: 
  • Together, they bring strong business acumen, extensive clinical and regulatory experience and leadership of successful teams that position us well to achieve our mission, said Keith Gottesdiener, M.D., Chief Executive Officer of Prime Medicine.
  • These esteemed leaders have deep expertise across their respective focus areas, each of which is key to the advancement of our novel Prime Editing technology.
  • Richard Brudnick, Chief Business Officer, brings extensive industry experience, including leading successful business development transactions, across multiple stages of development and an array of therapeutic areas.
  • The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene.

Nuvalent Appoints Anna Protopapas as Chair of Board of Directors

Retrieved on: 
Thursday, March 31, 2022

CAMBRIDGE, Mass., March 31, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, as Chair of its Board of Directors.

Key Points: 
  • She will assume the role of Board Chair from Cameron Wheeler, Ph.D., Partner at Deerfield Management, who will remain on Nuvalent's Board of Directors.
  • "With continued confidence in Nuvalent's approach and long-term vision, we welcome Anna as incoming Board Chair to further strengthen the team as we navigate the next phase of Nuvalent's growth."
  • We are fortunate to build on the strong foundation they have helped to establish as we transition Anna into the role of Board Chair," said James Porter, Ph.D., Chief Executive Officer at Nuvalent.
  • Ms. Protopapas has proven leadership in building and growing biotechnology companies, previously serving on the Board of Directors for ARIAD Pharmaceuticals, Bioverativ and Dicerna Pharmaceuticals.

Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer

Retrieved on: 
Tuesday, February 22, 2022

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022.
  • We are delighted to welcome Sarah, a biopharma veteran, to the Sigilon team, said Rogerio Vivaldi, M.D., President and CEO of Sigilon.
  • Prior to joining Sigilon Therapeutics, Dr. Yuan served as Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio.
  • Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform.

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

Retrieved on: 
Wednesday, January 5, 2022

Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. and globally.

Key Points: 
  • Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. and globally.
  • Dr. Vivaldi is currently the president and chief executive officer of Sigilon Therapeutics, Inc., where he also serves as a member of the company's board of directors.
  • While each rare disease impacts only a small number of people, they collectively affect an estimated 25-30 million Americans.
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Remedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development

Retrieved on: 
Monday, November 29, 2021

BOSTON, Nov. 29, 2021 /PRNewswire/ -- Remedium Bio, Inc., is pleased to announce the appointment of Dr. Alexey Seregin as Vice President of Research and Development.

Key Points: 
  • BOSTON, Nov. 29, 2021 /PRNewswire/ -- Remedium Bio, Inc., is pleased to announce the appointment of Dr. Alexey Seregin as Vice President of Research and Development.
  • Dr. Seregin brings a strong track record to Remedium Bio, leading a number of high-prolife gene therapy programs at his most recent appointment with Takeda R&D.
  • Previously, Dr. Seregin led Research and Development programs at Biogen, Solid Biosciences, and Bioverativ.
  • "We are excited to welcome Dr. Seregin to Remedium Bio," said Frank Luppino, Remedium's President and CEO.